Seagen

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Seagen reports robust Q4 earnings, poised for growth and innovation

Seagen's strong financial performance, focus on key products like ADCETRIS and PADCEV, and strategic investments in R&D position the company for continued growth.
While facing challenges in managing expenses and navigating competitive markets, Seagen's commitment to innovation and pipeline development presents opportunities for future success.
Overall, Seagen's performance in Q4 2022 reflects a company poised for growth, with a clear strategic focus on optimizing its commercial portfolio and advancing clinical programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.  The company was founded in 1997 and is headquartered in Bothell, Washington.

Seagen (SGEN) expects its portfolio of marketed drugs, which are approved for various cancer indications, to generate incremental sales and combat stiff competition.

Will Seagen's (SGEN) Portfolio of Drugs Help Combat Rivalry?

Seagen is now trading below the levels that implied a high probability of a buyout. Label expansion opportunities for approved products and the expanding pipeline will drive strong topline growth in the following years.

Standalone Seagen Is Starting To Look Attractive

Only one future study readout was talked about in Seagen's Q2 earnings call. However, six additional human trials are estimated to complete in the next 6 months.

Seagen: Upcoming Short- And Medium-Term Clinical Catalysts

Seagen (SGEN) signs an exclusive agreement with LAVA Therapeutics to develop and commercialize the latter's preclinical asset, LAVA-1223, targeting EGFR-expressing solid tumors.

Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223

Zai Lab Ltd.

BOTHELL, Wash. & SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage global biopharmaceutical company, today announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK® (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. TIVDAK is the f

Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

LAVA Therapeutics NV

BOTHELL, Wash. & UTRECHT, Netherlands & PHILADELPHIA--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an ad

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

Coca-Cola

T-Mobile US

The billionaire investor is a big believer in betting on America.

Worried About the Stock Market? Take Warren Buffett's Advice and Do This

FDA grants priority review to Seagen's (SGEN) sNDA for Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer. A decision is due on Jan 19, 2023.

Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) seeking accelerated approval for TUKYSA® (tucatinib) in combination with trastuzumab for adult patients with HER2-positive colorectal cancer who have received at least one prior treatment regimen for unresectable or metastatic disease. The sNDA submission is based on the results of the pivotal p

Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

Merck

BOTHELL, Wash. & TOKYO & RAHWAY, N.J.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN), Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K investigating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and PADCEV alone as first-line

Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

– Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab –  – Data highlighted in late-breaking presentation at the European Society for Medical Oncology (ESMO) Congress 2022 – TOKYO and BOTHELL, Wash. and RAHWAY, N.J.

Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Amazon

Biohaven Pharmaceutical Hld

Salesforce

Dollar General

Alphabet

Healthcare Realty Trust Inc

Eli Lilly

Microsoft

Neurocrine Biosciences

PayPal

Snowflake

Big investors are famous for breaking rank from the S&P 500 crowd. So when you see a few agreeing on a stock, it's worth paying attention.

15 Stocks Billionaire Investors Agree It's Smart To Buy Now

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2022, to be held September 9-13 in Paris, France. One of two late-breaking oral presentations will feature results from Cohort K of EV-103 (also known as KEYNOTE-869), a phase 1b/2 clinical trial conducted in partnership with Astellas. Cohort K is evaluating PADCEV® (enfortumab vedotin-ej

Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medical Oncology (ESMO) Congress

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 at 12:55 p.m. Eastern Time. The presentation will be webcast live and available for replay from the investor section of Seagen's website at investor.seagen.com. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative ca

Seagen to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

A steep valuation may force Merck to look elsewhere for portfolio growth.

Merck's Deal With Seagen May Have Fallen Through. Now What?

Merck's rumored takeover of cancer-focused biotech Seagen has stalled on price, according to a report Friday that sent SGEN stock tumbling. The post Merck's Rumored $40 Billion Seagen Takeover Hits A Snag On Price appeared first on Investor's Business Daily.

Merck's Rumored $40 Billion Seagen Takeover Hits A Snag On Price

A report says Merck's talks to acquire Seagen have stalled, with the companies failing to agree on a price.

Seagen Stock Tumbles on Report Possible Buyout by Merck Has Stalled

While investors are eagerly awaiting news on a Seagen tie-up, Merck offers upside even if the deal doesn't materialize.

Merck Looks Attractive, With or Without Seagen

Seagen lost a royalty battle Friday, but SGEN stock jumped on the potential the rumored Merck acquisition could be looming. The post Does Merck Finally Have The Fodder It Needs To Buy Seagen?

Does Merck Finally Have The Fodder It Needs To Buy Seagen?

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. (“Daiichi Sankyo”) relating to the parties' 2008 collaboration agreement for the use of Seagen's antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen on the interpretation of the contract. “While we are disappointed with the arbitration decision,

Seagen Statement on Outcome of Daiichi Sankyo Arbitration

Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.

Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe

Amgen

Chemocentryx

Global Blood Therapeutics

Pfizer

SPDR S&P Pharmaceuticals ETF

Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.

Get ready for more merger mania in pharma sector the rest of the year

Biogen

BioMarin Pharmaceutical

Bristol-Myers

Medpace Holdings

Thermo Fisher Scientific

Zimmer Biomet Hlds

You're tempted to increase exposure to stocks because of the market's strength. But you're still gun shy because of the painful selloff.

These eight health-care stocks can keep you invested in the market with less worry

Seagen (SGEN) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates.

Seagen's (SGEN) Earnings & Revenues Surpass Estimates in Q2

Seagen Inc. (NASDAQ:SGEN ) Q2 2022 Earnings Conference Call July 28, 2022 4:30 PM ET Company Participants Douglas Maffei - Vice President of Investor Relations Roger Dansey - Chief Medical Officer & Interim Chief Executive Officer Todd Simpson - Chief Financial Officer Chip Romp - Executive Vice President, Commercial U.S. Conference Call Participants Salveen Richter - Goldman Sachs Matthew Harrison - Morgan Stanley Cory Kasimov - JPMorgan Gena Wang - Barclays Andrew Berens - SVB Securities Michael Schmidt - Guggenheim Geoff Meacham - Bank of America Gregory Renza - RBC Capital Stephen Willey - Stifel Andy Hsieh - William Blair Joe Catanzaro - Piper Sandler Jay Olson - Oppenheimer Zhiqiang Shu - Berenberg Reni Benjamin - JMP Securities Ami Fadia - Needham Operator Good day and welcome to the Seagen Second Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.

Seagen Inc. (SGEN) CEO Roger Dansey on Q2 2022 Results - Earnings Call Transcript

News for Seagen Stock (SGEN)